Andrew Elbardissi

Andrew ElBardissi, MD, currently serves as a Partner at Deerfield Management since January 2017, bringing extensive experience in the healthcare sector. In addition to this role, Andrew holds board member positions at several companies, including Medical Microinstruments, Inc., Aurion Biotech, Bitteroot, Adela Bio, Encodia, Inc., Endologix LLC, Sema4, Reprieve Cardiovascular, and Element Science, Inc., showcasing a strong influence in medical innovation and biotechnology. Andrew's educational background includes an MBA from Harvard Business School, an MPH in Quantitative Methods from Harvard T.H. Chan School of Public Health, and a Doctor of Medicine (M.D.) from Mayo Clinic Alix School of Medicine.